Quintiles launches CRO in booming China drug market

In yet another sign of the eastward drift of clinical development work, Quintiles says it is setting up a new CRO in China to help developers with everything from clinical trial management to regulatory submissions. The move comes as Quintiles, which has a staff of 300 in the Asian country, is planning to double the number of workers it has there. "We have an aggressive growth plan for China," says Quintiles China GM Ling Zhen. Release

Suggested Articles

German researchers uncovered 28 antibodies that neutralize COVID-19 and are working with Boehringer Ingelheim to advance them into clinical testing.

Oragenics is ending a phase 2 study of its oral mucositis drug, yanking its IND application and switching its focus to a COVID-19 vaccine.

The vehicle, which Blackstone claims is the largest life sciences private fund, has committed close to $1 billion to companies including Alnylam.